GERMAN Angst
Guidance und Outlook sind doch klar on track, ich habe schlimmeres erwartet...
ERFORMANCE REVIEW, PRIORITY RESET & OUTLOOK
Focusing on sustainable and profitable growth Focusing & rightsizing organisation to overcome challenging market environment, and return to sustainable and profitable growth Shared R&D and Just – Evotec Biologics to replace EVT Execute & EVT Innovate segments in streamlined reporting structure as of Q1 2024 !! Expected annualised EBITDA improvement greater than € 40 m Evotec plans to update the market on its mid-term forecast with its H1 results Financial guidance for 2024 Group revenues expected to grow by a double-digit percentage (2023: € 781.4 m) !! Mid-single to low double digit percentage reduction of unpartnered research and development expenses expected (2023: € 64.8 m) !! Adjusted Group EBITDA expected to grow by a mid-double-digit percentage (2023: € 66.4 m) Refined guidance to be assessed together with new CEO; update planned for H1 results |